8-K - Lunai Bioworks Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Lunai Bioworks Inc. received a Nasdaq delisting determination on February 6, 2026, due to non-compliance with the minimum bid price requirement, as its stock closed below $1.00 for 30 consecutive business days. The company is not eligible for a compliance period due to a recent reverse stock split and has requested a hearing to appeal the determination, which could suspend the delisting pending the outcome.

Key Takeaways

1Nasdaq determined to delist Lunai Bioworks' securities from the Nasdaq Capital Market on February 6, 2026.

2The company is non-compliant with Nasdaq Listing Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share.

3The bid price closed below $1.00 for 30 consecutive business days from December 23, 2025, through February 5, 2026.

4The company is not eligible for a 180-day compliance period because it effected a 1-for-10 reverse stock split on September 30, 2025.

5Securities will be suspended from trading on February 18, 2026, unless a hearing is requested by February 13, 2026.

6The company has filed a request for a hearing before the Nasdaq Hearings Panel to appeal the determination.

Current Report Details

Event Type

Delisting

Regulation Fd

Disclosure

Mandatory

Variant

8-K

Items Reported

3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 6, 2026, Lunai Bioworks, Inc. (the “Company”) r

Delisting

$1.00$1.00

7.01

. Regulation FD Disclosure. In accordance with Nasdaq Listing Rule 5810(b), the Company is issuing this Current Report on Form 8-K to publicly disclose receipt

Regulation Fd

Exhibits (1)

8-K

FORM 8-K